SEC Form 4 · accession 0001209191-18-040022
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Silvia Noiman
Officer — Chief Executive Officer · Director
Period of report
Jun 6, 2018
Accepted (ET)
Jun 29, 2018 · 4:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001035354
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 6, 2018 | M | 349,400 | $0.0006 | A | 490,789 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F3 | $0.0006 | Jun 6, 2018 | M | 349,400 | D | — | Apr 26, 2024 | Common Stock | 349,400 | 0 | D |
Explanation of responses
- F1The option was issued pursuant to the Company's Eloxx Pharmaceuticals Ltd. Share Ownership and Option Plan (2013) and was priced at Israeli New Shekel 0.0020. This amount reflects the U.S. dollar equivalent of the exercise price as of the transaction date using an exchange rate of 1:3.5736, as reported by Bloomberg.
- F2Represents the total number of shares owned by the Reporting Person as of the date of filing.
- F3The option was fully vested and exercisable as of October 26, 2016.